Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.
Publication
, Journal Article
Bach, RG; Cannon, CP; Blazing, MA
Published in: JAMA Cardiol
February 1, 2020
Duke Scholars
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
February 1, 2020
Volume
5
Issue
2
Start / End Page
235 / 236
Location
United States
Related Subject Headings
- Simvastatin
- Humans
- Ezetimibe, Simvastatin Drug Combination
- Ezetimibe
- Anticholesteremic Agents
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Bach, R. G., Cannon, C. P., & Blazing, M. A. (2020). Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply. JAMA Cardiol, 5(2), 235–236. https://doi.org/10.1001/jamacardio.2019.5241
Bach, Richard G., Christopher P. Cannon, and Michael A. Blazing. “Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.” JAMA Cardiol 5, no. 2 (February 1, 2020): 235–36. https://doi.org/10.1001/jamacardio.2019.5241.
Bach RG, Cannon CP, Blazing MA. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply. JAMA Cardiol. 2020 Feb 1;5(2):235–6.
Bach, Richard G., et al. “Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply.” JAMA Cardiol, vol. 5, no. 2, Feb. 2020, pp. 235–36. Pubmed, doi:10.1001/jamacardio.2019.5241.
Bach RG, Cannon CP, Blazing MA. Interpreting the Benefit of Simvastatin-Ezetimibe in Patients 75 Years or Older-Reply. JAMA Cardiol. 2020 Feb 1;5(2):235–236.
Published In
JAMA Cardiol
DOI
EISSN
2380-6591
Publication Date
February 1, 2020
Volume
5
Issue
2
Start / End Page
235 / 236
Location
United States
Related Subject Headings
- Simvastatin
- Humans
- Ezetimibe, Simvastatin Drug Combination
- Ezetimibe
- Anticholesteremic Agents
- Acute Coronary Syndrome
- 3201 Cardiovascular medicine and haematology